The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 03, 2015

Filed:

Jul. 30, 2007
Applicants:

Jan Barciszewski, Poznan, PL;

Miroslawa Barciszewska, Poznan, PL;

Leszek Rychlewski, Poznan, PL;

Eliza Wyszko, Poznan, PL;

Iwona Gawronska, Poznan, PL;

Ryszard Zukiel, Poznan, PL;

Katarzyna Rolle, Gadki, PL;

Stanisaw Nowak, Poznan, PL;

Inventors:

Jan Barciszewski, Poznan, PL;

Miroslawa Barciszewska, Poznan, PL;

Leszek Rychlewski, Poznan, PL;

Eliza Wyszko, Poznan, PL;

Iwona Gawronska, Poznan, PL;

Ryszard Zukiel, Poznan, PL;

Katarzyna Rolle, Gadki, PL;

Stanisaw Nowak, Poznan, PL;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/1136 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01);
Abstract

The subject matters of this invention are a sequence of double-stranded RNA: ATN-RNA, intervention using interference RNA (iRNAi), use of a sequence of double-stranded RNA: ATN-RNA, a method of treating a brain tumor and a method of inhibiting a brain tumor cells which express tenascin, a kit for inhibiting cancer cell which expresses tenascin and a method for a kit preparation in a brain tumor therapy. Malignant gliomas preferentially express a number of surface markers that may be exploited as therapeutic targets, including tenascin-C, an extracellular matrix glycoprotein that is ubiquitously expressed by malignant gliomas and probably contributes to tumor cell adhesion, invasion, migration and proliferation. For tenascin-C inhibition, RNA interference intervention (iRNAi) approach have been applied.


Find Patent Forward Citations

Loading…